Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations

Athanasios Pouptsis; Leyla Swafe; Maneesha Patwardhan; Chara Stavraka

doi:10.3389/fonc.2020.553080

Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations

Athanasios Pouptsis, Leyla Swafe, Maneesha Patwardhan, Chara Stavraka

Research output: Contribution to journal › Review article › peer-review

18 Citations (Scopus)

Abstract

Hereditary breast cancer accounts for 5%-10% of breast cancer cases. The majority of familial cases have been linked to germline mutations in BRCA1 and BRCA2 genes, though other high penetrance susceptibility genes have also been identified through genomic testing advances. Optimal surgical treatment for these patients, who are of a younger age, has several challenges as it usually involves aggressive therapeutic and risk reducing interventions. At the same time, the therapeutic armamentarium for BRCA1/2 mutation carriers apart from platinum salts, has been enriched with the addition of poly-ADP ribose polymerase (PARP) inhibitors with promising outcomes. In this review we provide a succinct and comprehensive overview of the surgical and systemic treatment options for patients with BRCA1/2 mutation related breast cancer and an update on the most recent systemic treatment advances.

Original language	English
Pages (from-to)	553080
Journal	Frontiers in oncology
Volume	10
DOIs	https://doi.org/10.3389/fonc.2020.553080
Publication status	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2020.553080

Cite this

@article{4517f56f0ae3410a9173615edeed60d1,

title = "Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations",

abstract = "Hereditary breast cancer accounts for 5%-10% of breast cancer cases. The majority of familial cases have been linked to germline mutations in BRCA1 and BRCA2 genes, though other high penetrance susceptibility genes have also been identified through genomic testing advances. Optimal surgical treatment for these patients, who are of a younger age, has several challenges as it usually involves aggressive therapeutic and risk reducing interventions. At the same time, the therapeutic armamentarium for BRCA1/2 mutation carriers apart from platinum salts, has been enriched with the addition of poly-ADP ribose polymerase (PARP) inhibitors with promising outcomes. In this review we provide a succinct and comprehensive overview of the surgical and systemic treatment options for patients with BRCA1/2 mutation related breast cancer and an update on the most recent systemic treatment advances.",

author = "Athanasios Pouptsis and Leyla Swafe and Maneesha Patwardhan and Chara Stavraka",

note = "Copyright {\textcopyright} 2020 Pouptsis, Swafe, Patwardhan and Stavraka.",

year = "2020",

doi = "10.3389/fonc.2020.553080",

language = "English",

volume = "10",

pages = "553080",

journal = "Frontiers in oncology",

issn = "2234-943X",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Surgical and Systemic Treatment of Hereditary Breast Cancer

T2 - A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations

AU - Pouptsis, Athanasios

AU - Swafe, Leyla

AU - Patwardhan, Maneesha

AU - Stavraka, Chara

PY - 2020

Y1 - 2020

N2 - Hereditary breast cancer accounts for 5%-10% of breast cancer cases. The majority of familial cases have been linked to germline mutations in BRCA1 and BRCA2 genes, though other high penetrance susceptibility genes have also been identified through genomic testing advances. Optimal surgical treatment for these patients, who are of a younger age, has several challenges as it usually involves aggressive therapeutic and risk reducing interventions. At the same time, the therapeutic armamentarium for BRCA1/2 mutation carriers apart from platinum salts, has been enriched with the addition of poly-ADP ribose polymerase (PARP) inhibitors with promising outcomes. In this review we provide a succinct and comprehensive overview of the surgical and systemic treatment options for patients with BRCA1/2 mutation related breast cancer and an update on the most recent systemic treatment advances.

AB - Hereditary breast cancer accounts for 5%-10% of breast cancer cases. The majority of familial cases have been linked to germline mutations in BRCA1 and BRCA2 genes, though other high penetrance susceptibility genes have also been identified through genomic testing advances. Optimal surgical treatment for these patients, who are of a younger age, has several challenges as it usually involves aggressive therapeutic and risk reducing interventions. At the same time, the therapeutic armamentarium for BRCA1/2 mutation carriers apart from platinum salts, has been enriched with the addition of poly-ADP ribose polymerase (PARP) inhibitors with promising outcomes. In this review we provide a succinct and comprehensive overview of the surgical and systemic treatment options for patients with BRCA1/2 mutation related breast cancer and an update on the most recent systemic treatment advances.

U2 - 10.3389/fonc.2020.553080

DO - 10.3389/fonc.2020.553080

M3 - Review article

C2 - 33194613

SN - 2234-943X

VL - 10

SP - 553080

JO - Frontiers in oncology

JF - Frontiers in oncology

ER -

Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this